InvestorsHub Logo
Followers 25
Posts 2697
Boards Moderated 2
Alias Born 09/15/2011

Re: None

Wednesday, 03/05/2025 10:05:46 AM

Wednesday, March 05, 2025 10:05:46 AM

Post# of 235018
https://onco-this-week.com/promising-survival-observations-in-mtnbc-patients-treated-with-leronlimab-announced/

March 4, 2025
Trial Results
TNBC

Dr. Jacob Lalezari, CEO of CytoDyn, added: “These provocative observations of improved survival in patients with mTNBC and prior treatment failure in the metastatic setting, including reported clearance of disease in a group of long-term survivors, provides early clinical evidence of leronlimab’s potential impact in the treatment of TNBC and other solid tumors. I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”

Read the full story on "Promising Survival Observations in mTNBC Patients Treated with Leronlimab Announced"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News